European Commission Approves Merck’s KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults Read more
Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma Read more
Primrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA Medicines Read more
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect Read more
European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk Read more
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib Read more
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Read more
EC Approves Astellas’ PADCEVTM (enfortumab vedotin) in Combination with KEYTRUDA (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer Read more
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH Read more